Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Pharmaceuticals; drugs; expenditures; medication; medicine; health care; monopoly; telemedicine; prescription; generic; brand-name; martin skreli; thiola; overpricing; securities; transparency legislation; drug pricing; Ro; anti-trust; privacy laws; bargain hunting; rural; medical facilities; access to healthcare; price controls; patent laws; drug importation; S5338A; NYPCTA; New York; Association for Accessible Medicine v. Frosh; Maryland; Drug Price Competition and Patent Term Restoration Act; Hatch-Waxman Act; ANDA; FDA; Affordable Care Act; Treasury Department; Federal Supplementary Medical Insurance Trust Fund; MMA; Medicare; Medicaid; Canada; Health and Human Services; Vermont v. Leavitt; Controlled Substance Act; Anti-Kickback statute; Stark law; mens rea; HIPAA; CMS (1)
- Sarbanes-Oxley; SEC; Dodd-Frank Act; initial public offering; Securities Exchange Act; proxy statements; Rule 14a-11; JOBS Act; enforcement; corporate governance; (1)
- Science; Technology; Patents; Health; Healthcare; Research and development; patent validity; trade secrecy; drugs; patent protection; biopharmaceutical companies; Intellectual Property; United States Patent and Trademark Office; Uniform Trade Secrets Act; Defend Trade Secrets Act; COVID-19; (1)
Articles 1 - 3 of 3
Full-Text Articles in Law
Navigating A Multi-Billion Dollar Industry: Protecting Drug-Related Inventions To Further Research And Development, Minal Patel
Navigating A Multi-Billion Dollar Industry: Protecting Drug-Related Inventions To Further Research And Development, Minal Patel
Brooklyn Journal of Corporate, Financial & Commercial Law
Even with advancements in science and technology, pharmaceuticals continue to find themselves tethered to patent protection guidelines that once ensured revenue would continue to flow and provide funding for the next blockbuster drug or antibodies. However, as the Federal Circuit appears to inch towards unpredictability in the realm of patent validity, challenges involving patenting are imminent. In fact, gaps are forming in the ability of pharmaceuticals to further research and develop drugs. This Note proposes a solution that encapsulates a more precise standard supported by economic and policy rationales to determine patent validity. It begins with the general requirements of …
Federalized Corporate Governance: The Dream Of William O. Douglas As Sarbanes-Oxley Turns 20, Joan Macleod Heminway
Federalized Corporate Governance: The Dream Of William O. Douglas As Sarbanes-Oxley Turns 20, Joan Macleod Heminway
Brooklyn Journal of Corporate, Financial & Commercial Law
The federalization of U.S. corporate governance has been a topic of conversation among policymakers from the very beginning of federal securities law in the New Deal era. Among the early proponents of a federalized system of corporate governance oversight was William O. Douglas—perhaps best known as the longest-serving U.S. Supreme Court justice, but who also was a former commissioner and chair of the U.S. Securities and Exchange Commission. Reflecting on Douglas’s federal corporate governance ideas, Professor Roberta Karmel wrote a law review article for the Delaware Journal of Corporate Law, published in 2005, commenting on the extent and nature of …
Pharmaceutical Drug Pricing: The Internet As A Solution For This Health Issue Turned Financial Issue, Thomas P. Kelly
Pharmaceutical Drug Pricing: The Internet As A Solution For This Health Issue Turned Financial Issue, Thomas P. Kelly
Brooklyn Journal of Corporate, Financial & Commercial Law
Over the course of five decades, American annual expenditure on pharmaceutical drugs has increased by more than $350 billion. This drastic increase has led many patients to struggle to afford their necessary, and potentially life-saving, medications. Today’s high pharmaceutical prices are largely due to the fact that name-brand drug manufacturers have few restrictions on how much they can charge for their products. Additionally, name-brand manufacturers are able to monopolize the manufacture of their drugs because patent laws prevent other manufacturers from using the formula of these drugs for two decades. To combat these high prices, this Note proposes a partnership …